Related Experiment Video
Updated: Oct 8, 2025
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.0K
Double-Edged Sword: A Case with Withdrawal-Emergent Dyskinesia
Turk Psikiyatri Dergisi = Turkish Journal of Psychiatry
|December 29, 2021
Summary
Withdrawal-emergent dyskinesia (WED) causes involuntary movements after antipsychotic changes. Early detection and treatment of WED are crucial for improving patient quality of life and preventing tardive dyskinesia.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Tardive dyskinesia (TD) involves involuntary movements from long-term neuroleptic use, impacting quality of life.
- Withdrawal-emergent dyskinesia (WED) presents with involuntary movements after antipsychotic medication adjustments.
- WED differs from TD in affected body parts and duration, with no established treatment consensus.
Observation:
- This report details a case of WED in a bipolar I disorder patient treated with clozapine after haloperidol discontinuation.
- The patient experienced WED following haloperidol cessation due to adverse effects.
Findings:
- WED involves involuntary movements primarily affecting the neck, trunk, and limbs, typically resolving faster than TD.
- Treatment options for WED include restarting the previous antipsychotic or switching to an atypical agent with low dopamine D2 receptor affinity.
Implications:
- WED is a predictor of tardive dyskinesia, highlighting the importance of early detection and management.
- Clinicians must consider potential dyskinesias when altering antipsychotic treatments.
- Further research is needed to establish a standardized treatment approach for WED.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
435
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
435
01:20Antiepileptic Drugs: Potassium Channel Activators
335
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
335
01:19Depolarizing Blockers: Pharmocokinetics
403
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
403
01:21Skeletal Muscle Relaxants: Adverse Effects
515
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
515
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
724
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
724
01:17Drugs for Treatment of Diarrhea-Predominant IBS
350
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
350